The drugmaker has reported top-line results from the phase 1/2 EPCORE trial of epcoritamab as a third-line therapy for relapsed/refractory LBCL, revealing an overall response rate of 63% and a ...

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.

There are currently two drugs that are approved by the Food and Drug Administration (FDA) to treat diffuse large B-cell ...

Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed/refractory DLBCL. The regimen also significantly extended survival. The addition of ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of patients with relapsed or refractory or R/R, follicular ...